MedTrace Logo

AMCPR (Augmented-Medication CardioPulmonary Resuscitation) Trial for OHCA

NCT03191240 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2022-03-08

No results posted yet for this study

Summary

The investigators aimed to evaluate the effect of AMCPR (Augmented-Medication CardioPulmonary Resuscitation: administration of additional vasopressin to titrate to arterial diastolic blood pressure over 20 mmHg) on cardiopulmonary resuscitation results and outcomes in out-of-hospital cardiac arrest patients.

Conditions

  • Out-of-Hospital Cardiac Arrest

Interventions

DRUG

Vasopressins

Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation

DRUG

Normal saline

Placebo

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Won Young Kim, MD, PhD · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-31
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03191240 on ClinicalTrials.gov